Skip to main content

Table 2 Comparison in efficacy between RCA and heparin anticoagulation for IHD

From: Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study

Variables Before inverse probability of treatment weighting After inverse probability of treatment weighting
IHD sessions with RCA (n = 124) IHD sessions with heparin (n = 84) p-value IHD sessions with RCA (n = 112) IHD sessions with heparin (n = 82) p-value |d|
Prescribed duration, min 271 ± 92 252 ± 59 0.35 271 ± 94 251 ± 57 0.07 0.250
Delivered duration, min 225 ± 84 234 ± 70 0.32 228 ± 78 229 ± 71 0.91 0.017
Difference between prescribed and delivered duration, min 45 ± 97 18 ± 50 0.01 43 ± 97 22 ± 56 0.07 0.262
Prescribed blood flow, mL/min 237 ± 39 257 ± 33 0.02 243 ± 40 254 ± 31 0.06 0.296
Delivered blood flow, mL/min 232 ± 36 245 ± 31 0.11 237 ± 37 236 ± 30 0.82 0.037
Difference between prescribed and delivered blood flow, mL/min 5 ± 19 12 ± 26 0.04 6 ± 18 18 ± 28 0.003 0.533
Prescribed dialysate flow, mL/min 481 ± 59 490 ± 46 0.43 488 ± 57 484 ± 52 0.70 0.070
Delivered dialysate flow, mL/min 485 ± 52 488 ± 50 0.81 490 ± 54 482 ± 57 0.39 0.159
Prescribed ultrafiltration, L 1.19 ± 0.98 1.30 ± 0.97 0.71 1.22 ± 0.99 1.20 ± 0.98 0.92 0.016
Net ultrafiltration at the end of session, L 0.96 ± 0.92 1.13 ± 0.91 0.33 1.02 ± 0.91 1.03 ± 0.94 0.93 0.015
Difference between prescribed and net ultrafiltration, L 0.23 ± 0.51 0.17 ± 0.34 0.34 0.20 ± 0.48 0.17 ± 0.35 0.65 0.069
Kt/V per hour 0.247 ± 0.068 0.227 ± 0.063 0.08 0.243 ± 0.072 0.217 ± 0.063 0.02 0.392
Kt/V at the end of session 0.95 ± 0.38 0.89 ± 0.32 0.98 0.93 ± 0.38 0.84 ± 0.32 0.61 0.242
Kt at the end of session 33.2 ± 13.4 34.5 ± 12.7 0.58 33.7 ± 13.5 32.0 ± 12.6 0.42 0.126
Kt/V at the end of session in 2015 0.97 ± 0.37 0.86 ± 0.30 0.53 NE NE   
Kt/V at the end of session in 2017 0.91 ± 0.41 0.92 ± 0.33 0.51 NE NE   
Kt at the end of session in 2015 31.9 ± 10.9 31.1 ± 10.3 0.80 NE NE   
Kt at the end of session in 2017 35.0 ± 16.1 37.3 ± 13.9 0.54 NE NE   
  1. NE not evaluated (Inverse probability of treatment weighting was not applied to the subgroup analyses in 2015 and 2017), RCA regional citrate anticoagulation, IHD intermittent hemodialysis